Publication Type:

Journal Article


Carbohydrate Polymers, Volume 93, Number 2, p.661-669 (2013)



Antibodies, antineoplastic agent, Antineoplastic Agents, Antitumor, article, Biological, Carboxymethyl chitosan, Cell death, Cell Line, Cetuximab, chemistry, chitosan, Drug delivery, drug delivery system, Drug Delivery Systems, drug derivative, drug effect, drug screening, Drug Screening Assays, EGFR, Electron, Epidermal Growth Factor, epidermal growth factor receptor, erythrocyte, Erythrocytes, flow cytometry, gelation, Hemolysis, human, Humanized, Humans, Medical nanotechnology, metabolism, methodology, microscopy, Monoclonal, Monoclonal antibodies, monoclonal antibody, nanoparticle, Nanoparticles, Nanotechnology, O carboxymethylchitosan, O-carboxymethylchitosan, Oncology, oxazine derivative, Oxazines, paclitaxel, particle size, Pharmaceutical, Receptor, resazurin, Scanning, scanning electron microscopy, Targeted drug delivery, Tumor, tumor cell line, tumor marker, Tumor Markers, ultrastructure, xanthene derivative, Xanthenes


Nanoparticle mediated delivery of antineoplastic agents, functionalized with monoclonal antibodies has achieved extraordinary potential in cancer therapy. The objective of this study was to develop a drug delivery system comprising O-carboxymethyl chitosan (O-CMC) nanoparticles, surface-conjugated with Cetuximab (Cet) for targeted delivery of paclitaxel (PTXL) to Epidermal Growth Factor Receptor (EGFR) over-expressing cancer cells. Nanoparticles around 180 ± 35 nm and negatively charged were prepared through simple ionic gelation technique. The alamar blue assay indicated that these targeted nanoparticles displayed a superior anticancer activity compared to non-targeted nanoparticles. The nanoformulation triggered enhanced cell death (confirmed by flow cytometry) due to its higher cellular uptake. The selective uptake of Cet-PTXL-O-CMC nanoparticles by EGFR +VE cancer cells (A549, A431 and SKBR3) compared to EGFR -VE MIAPaCa-2 cells confirms the active targeting and delivery of PTXL via the targeted nanomedicine. Cet-PTXL-O-CMC nanoparticles can be used a promising candidate for the targeted therapy of EGFR over expressing cancers. © 2012 Elsevier Ltd.


cited By 15

Cite this Research Publication

, “Cetuximab conjugated O-carboxymethyl chitosan nanoparticles for targeting EGFR overexpressing cancer cells”, Carbohydrate Polymers, vol. 93, pp. 661-669, 2013.